antihistaminic

Thonzylamine (neohetramine) 是可口服的H1组胺受体拮抗剂，具有抗组胺和抗过敏特性，可用于鼻充血、过敏性结膜炎和其他过敏性疾病的研究。

Tripelennamine hydrochloride (Pyribenzamine hydrochloride) 是一种组胺 H1 拮抗剂，具有低镇静作用，但经常刺激胃肠道。

Elbanizine 显示出抗过敏、抗哮喘、抗组胺和解痉的活性。

Pheniramine maleate (Trimetose) 是一种具有抗组胺和血管扩张特性的烷基胺衍生物，可与组胺 H1 受体结合，从而抑制磷脂酶 A2 和内皮源性松弛因子一氧化氮的产生。

Phenothiazine (ENT 38) 是一种抗生素，具有杀虫，抗菌，驱虫和杀真菌活性。它也可研究神经系统疾病。

Levocetirizine Dihydrochloride (Xyzal Dihydrochloride)是一种第三代外周H1受体拮抗剂。作为抗组胺化合物，它特异性地针对组胺H1受体。Levocetirizine Dihydrochloride 是西替利嗪的R-对映体，使其对H1受体的亲和力高于S-对映体。因此，Levocetirizine Dihydrochloride 在治疗过敏性鼻炎和慢性特发性荨麻疹方面有效。

Astemizole (Laridal) 是一种长效、非镇静抗组胺药，用于治疗季节性过敏性鼻炎、哮喘、过敏性结膜炎和慢性特发性荨麻疹。它是组胺 H1 受体的拮抗剂，IC50值为 4 nM，还阻断 hERG K+通道，IC50值为 0.9 nM，具有抗胆碱能和止痒作用。

Terfenadine ((±)-Terfenadine) 是一种hERG 开放通道抑制剂，IC50为 204 nM。它也是一种 H1 组胺受体拮抗剂，通过调节Ca2+稳态在黑素瘤细胞中起到有效的细胞凋亡诱导作用。 Terfenadine 诱导 ROS 依赖性细胞凋亡，同时激活Caspase-4，-2，-9。

Fexofenadine hydrochloride 是 terfenadine 的羧化代谢衍生物和长效选择性组胺 H1 受体拮抗剂，具有抗组胺活性。

Dimetholizine 具有抗高血压和抗组胺特性。它主要靶向 Histamine H1 receptor，并显示对 Dopamine D2 和 5-HT1A receptors 的结合亲和力。预测研究还显示 Dimetholizine 为 alpha1D-Adrenergic blocker。

Levocabastine HCl is an agent with antihistaminic activity.

3-CPMT (FC-1) 是一种多巴胺摄取抑制剂和一种有效的长效抗组胺剂。

AHR-13268D is a new agent of antiallergic antihistaminic.

Bromodiphenhydramine hydrochloride 是一种控制皮肤的新型抗组胺药。

Levomequitazine is an antihistaminic drug candidate.

Piprinhydrinate is a Histamine H₁-receptor antagonist (H₁-antihistaminic).

Secoverine is a selective muscarinic receptor antagonist that was studied as a neurotropic spasmolytic agent. It was shown that the drug had no nicotinolytic or antihistaminic activity, a moderate antisterotonic activity, an inhibiting effect on the noradrenaline uptake mechanism of the vas deferens and marked local anesthetic activity.

Noberastine citrate, a histamine H1 antagonist, has potent and specific peripheral antihistaminic activity. Noberastine, a furan derivative of nor-astemizole (an astemizole metabolite), has been shown to have a more rapid onset, and shorter duration of action than astemizole with peak antihistaminic activity at 4h following ingestion. Noberastine is rapidly absorbed and the peak plasma levels are obtained within 2 h of oral dosing. In preclinical studies Noberastine has been shown to lack central nervous system effects. After subacute (steady-state) administration of noberastine, there was increasing inhibition of weal and flare formation with higher doses of the drug. The 30 mg daily dose showed maximum antihistaminic effects.

Noberastine maleate, a histamine H1 antagonist, has potent and specific peripheral antihistaminic activity. Noberastine, a furan derivative of nor-astemizole (an astemizole metabolite), has been shown to have a more rapid onset, and shorter duration of action than astemizole with peak antihistaminic activity at 4h following ingestion. Noberastine is rapidly absorbed and the peak plasma levels are obtained within 2 h of oral dosing. In preclinical studies Noberastine has been shown to lack central nervous system effects. After subacute (steady-state) administration of noberastine, there was increasing inhibition of weal and flare formation with higher doses of the drug. The 30 mg daily dose showed maximum antihistaminic effects.

Embramine (hydrochloride) 为具有抗组胺及抗胆碱能特性的单乙醇胺类化合物。